Multisite study of the relationships between antemortem [ 11 C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

R La Joie; N Ayakta; WW Seeley; E Borys; AL Boxer; C DeCarli; V Doré; LT Grinberg; E Huang; JH Hwang; MD Ikonomovic; C Jack; WJ Jagust; LW Jin; WE Klunk; J Kofler; OH Lesman-Segev; SN Lockhart; VJ Lowe; CL Masters; CA Mathis; CL McLean; BL Miller; D Mungas; JP O'Neil; JM Olichney; JE Parisi; RC Petersen; HJ Rosen; CC Rowe; S Spina; P Vemuri; VL Villemagne; ME Murray; GD Rabinovici

Journal article

Multisite study of the relationships between antemortem [ 11 C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

R La Joie, N Ayakta, WW Seeley, E Borys, AL Boxer, C DeCarli, V Doré, LT Grinberg, E Huang, JH Hwang, MD Ikonomovic, C Jack, WJ Jagust, LW Jin, WE Klunk, J Kofler, OH Lesman-Segev, SN Lockhart, VJ Lowe, CL Masters Show all

Alzheimer S and Dementia | ELSEVIER SCIENCE INC | Published : 2019

DOI: 10.1016/j.jalz.2018.09.001

Abstract

Introduction: We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [ 11 C]PIB–positron emission tomography ([ 11 C]PIB-PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ-PET quantification. Methods: Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. Results: CL values increased with each CERAD neuritic plaque score increment (median −3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET-pathology associations were compa..

View full abstract

University of Melbourne Researchers

Christopher Rowe Author

Victor Villemagne Author

Related Projects (2)

MOLECULAR IMAGING OF NEURODEGENERATION

This research proposal outlines studies aimed at identifying specific biomarkers of neurodegeneration. Given the complexity and clinical ove..

BIOMARKERS TO AID CLINICAL TRIALS FOR NEURODEGENERATIVE DISEASE

Alzheimer’s disease and Parkinson’s disease continue to affect more Australians every year, due to an ageing population and the lack of effe..

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

UCSF-National Institutes of Health (R01-AG045611, P01-AG1972403, P50-AG023501, R01-AG032306, K24 AG053435), Tau Consortium, Consortium for Frontotemporal Dementia Research, John Douglas French Alzheimer's Foundation, and Alzheimer's Association (AARF-16-443577); UCD-National Institutes of Health (P30 AG010129, P01 AG012435, R01 AG021028, R01 AG031563); UC Berkeley-National Institute of Health (R01AG034570); Mayo-National Institutes of Health (R01 NS097495, U01 AG006786, P50 AG016574/P1, R01 AG011378, R01 AG041851, R01 AG054449), the GHR Foundation, the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation, Liston Award, Elsie and Marvin Dekelboum Family Foundation, and Schuler Foundation. AIBL-NHMRC Research Fellowship 1046471, NHMRC Program Grant 1132604; and UPitt: National Institute of Health (P50 AG005133, RF1 AG025516, P01 AG025204).